Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Establishment and characterization of a novel patient-derived cell line from conventional central grade 3 chondrosarcoma, NCC-CS1-C1.

Human cell - 8 Dec 2024

Noguchi Rei, Ono Takuya, Osaki Julia, Adachi Yuki, Iwata Shuhei, Shiota Yomogi, Yanagihara Kazuyoshi, Nishino Shogo, Funada Takaya, Ogura Koichi, Yoshida Akihiko, Kawai Akira, Kondo Tadashi

Abstract excerpt

Chondrosarcoma (CS) is a malignant tumor that produces cartilaginous matrix and is the second most common primary bone sarcoma. CS encompasses a range of histological subtypes, with high-grade conventional central CS being particularly rare, occurring at a rate of 1.81 cases per 1 million person-years. Complete surgical resection is the standard curative treatment for this subtype, as radiation therapy and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone Neoplasms
Share to Bortezomib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chondrosarcoma

Share to Depsipeptides

Share to Doxorubicin

Share to Isocitrate Dehydrogenase

Share to Neoplasm Grading

Share to Oligopeptides

Source

Identifiers

PMID: 39645627
DOI: 10.1007/s13577-024-01152-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Establishment and characterization of a novel patient-derived cell line from conventional central grade 3 chondrosarcoma, NCC-CS1-C1.PMID 39645627Read ↗

Three new chondrosarcoma cell lines: one grade III conventional central chondrosarcoma and two dedifferentiated chondrosarcomas of bone.Semantic proximity Read ↗

Advances in the Molecular Biology of Chondrosarcoma for Drug Discovery and Precision MedicineSemantic proximity Read ↗

Olutasidenib in recurrent/relapsed locally advanced or metastatic IDH1-mutated chondrosarcoma: phase 1b/2 trial.Semantic proximity Read ↗

Establishment and characterization of PUMC-DDCS1: a novel patient-derived cell line of dedifferentiated chondrosarcomaSemantic proximity Read ↗

Establishment and characterization of a novel dedifferentiated chondrosarcoma cell line, SMU-DDCS, harboring an IDH1 mutation.Semantic proximity Read ↗

Establishment and characterization of novel patient-derived cell lines from giant cell tumor of bone.Semantic proximity Read ↗

Establishment and characterization of two novel patient-derived cell lines from giant cell tumor of bone: NCC-GCTB8-C1 and NCC-GCTB9-C1Semantic proximity Read ↗

Presence of IDH2 and TP53 mutations significantly reduces survival of patients with chondrosarcoma.Semantic proximity Read ↗

Chondrosarcoma: biology, genetics, and epigeneticsSemantic proximity Read ↗

Establishment and characterization of two novel patient-derived cell lines from myxofibrosarcoma: NCC-MFS7-C1 and NCC-MFS8-C1Semantic proximity Read ↗

IDH mutations in G2-3 conventional central bone chondrosarcoma: a mono institutional experience.Semantic proximity Read ↗

Chondrosarcoma: An overview of clinical behavior, molecular mechanisms mediated drug resistance and potential therapeutic targetsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.